Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective ...

There are many options to treat metastatic non-small-cell lung cancer (NSCLC). Your treatment plan will depend ... are good at hiding from your immune system. Immunotherapy boosts your defenses ...

Standard chemotherapy (chemo) was once the only treatment for advanced non-small-cell lung cancer (NSCLC ... It triggers your immune system to attack your cancer. If your tumor has a high ...

The European Commission (EC) has granted approval to Bristol Myers Squibb's (BMS) perioperative regimen of neoadjuvant Opdivo ...

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

One expert explains how a break in TKI treatment could alleviate some toxicities, such as rash, for patients with non-small cell lung cancer. Circulating tumor DNA (ctDNA)-adaptive treatment ...

The next-generation tyrosine kinase inhibitor Augtyro (repotrectinib) represents a new treatment option for patients with locally advanced (cancer that has spread to nearby tissue or lymph nodes) or ...

Driver genes are not always sufficiently investigated before treatment in a patient with advanced or recurrent NSCLC. This study aimed to evaluate how much biomarker testing and drug therapy is ...

Ivonescimab represents a new, more effective, and safer "chemotherapy-free" option for the first-line treatment of NSCLC. Ivonescimab is the first bispecific antibody approved globally with a dual ...

Of the 90 patients diagnosed with advanced NSCLC in the liquid biopsy group, 23% started targeted therapy on the basis of their plasma ctDNA findings alone; the median time to treatment was 27 days.

Researchers say it could inform clinical intervention, including whether to restart or intensify treatment. In the continuing evolution ... patients with non-small cell lung cancer (NSCLC) with ...

The purpose of the pre-NDA meeting was to discuss the company’s planned NDA for repotrectinib for the treatment of ROS1+ advanced NSCLC. The FDA agreed with the company’s plan to provide data ...